- Home
- CORT
as 02-21-2025 4:00pm EST
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
Upcoming Earnings Alert:
Get ready for potential market movements as Corcept Therapeutics Incorporated CORT prepares to release earnings report on 26 Feb 2025.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 7.1B | IPO Year: | N/A |
| Target Price: | $97.00 | AVG Volume (30 days): | 894.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.26 | EPS Growth: | 57.97 |
| 52 Week Low/High: | $20.84 - $75.00 | Next Earning Date: | 02-26-2025 |
| Revenue: | $628,555,000 | Revenue Growth: | 39.67% |
| Revenue Growth (this year): | 46.47% | Revenue Growth (next year): | 21.49% |
Stock Insider Trading Activity of Corcept Therapeutics Incorporated (CORT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Swisher Daniel N JR | CORT | Director | Feb 10 '25 | Sell | $68.08 | 2,200 | $149,776.00 | 0 | |
| Lyon Joseph Douglas | CORT | See Remarks | Feb 3 '25 | Sell | $66.92 | 5,000 | $334,600.00 | 8,759 | |
| Maduck Sean | CORT | See Remarks | Feb 3 '25 | Sell | $66.92 | 20,000 | $1,338,400.00 | 85,318 | |
| Swisher Daniel N JR | CORT | Director | Jan 10 '25 | Sell | $50.54 | 2,200 | $111,188.00 | 0 | |
| Robb Gary Charles | CORT | Chief Business Officer | Jan 2 '25 | Sell | $50.50 | 11,000 | $555,551.70 | 20,119 | |
| Lyon Joseph Douglas | CORT | See Remarks | Jan 2 '25 | Sell | $50.39 | 5,000 | $251,950.00 | 8,759 | |
| Maduck Sean | CORT | See Remarks | Jan 2 '25 | Sell | $50.39 | 20,000 | $1,007,800.00 | 85,318 | |
| Swisher Daniel N JR | CORT | Director | Dec 10 '24 | Sell | $59.46 | 2,200 | $130,812.00 | 0 |
Latest Corcept Therapeutics Incorporated News
CORT Breaking Stock News: Dive into CORT Ticker-Specific Updates for Smart Investing
Argus Research
3 days ago
CORT: Raising target price to $76.00
Investor's Business Daily
3 days ago
Recursion Pharmaceuticals Stock Scores RS Ratings Over 90
Investor's Business Daily
3 days ago
Incyte Stock Sees Relative Strength Rating Rise To 71
Business Wire
9 days ago
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call
Simply Wall St.
17 days ago
3 US Growth Companies With High Insider Ownership Expecting Up To 22% Revenue Growth
Argus Research
17 days ago
CORT: Raising target price to $70.00
Zacks
19 days ago
Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol
Zacks
22 days ago
Corcept (CORT) Soars 13.6%: Is Further Upside Left in the Stock?
Compare CORT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CORT Corcept Therapeutics Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.